Bouchardeau F - Search Results

1

[Hepatitis B virus DNA as a marker of viral multiplication: comparison with HBe antigen and anti-HBe antibody].

Thiers V, Bouchardeau F, Courouce AM, Tiollais P, Brechot C. Thiers V, et al. Among authors: bouchardeau f. Presse Med. 1986 Jun 28;15(26):1219-22. Presse Med. 1986. PMID: 2944091 French.

2

[Use of hepatitis B virus vaccine in volunteer donors already immunized against this virus].

Bouchardeau F, Le Marrec N, Courouce AM, Boulard G, Soulier JP. Bouchardeau F, et al. Rev Fr Transfus Immunohematol. 1982 Oct;25(5):473-85. doi: 10.1016/s0338-4535(82)80051-2. Rev Fr Transfus Immunohematol. 1982. PMID: 7163728 French.

3

Determination of hepatitis B virus subtypes by an enzyme immunoassay method using monoclonal antibodies to type-specific epitopes of HBsAg.

Laperche S, Girault A, Beaulieu MJ, Bouchardeau F, Couroucé AM. Laperche S, et al. Among authors: bouchardeau f. J Viral Hepat. 2001 Nov;8(6):447-53. doi: 10.1046/j.1365-2893.2001.00318.x. J Viral Hepat. 2001. PMID: 11703576

4

Hepatitis C virus (HCV) infection in haemodialysed patients: HCV-RNA and anti-HCV antibodies (third-generation assays).

Couroucé AM, Bouchardeau F, Chauveau P, Le Marrec N, Girault A, Zins B, Naret C, Poignet JL. Couroucé AM, et al. Among authors: bouchardeau f. Nephrol Dial Transplant. 1995;10(2):234-9. Nephrol Dial Transplant. 1995. PMID: 7538650

5

Detection of hepatitis C virus by polym erase chain reaction in haemodialysed patients in relationship to anti-HCV status.

Bouchardeau F, Chauveau P, Le Marrec N, Girault A, Zins B, Couroucé AM. Bouchardeau F, et al. Res Virol. 1993 May-Jun;144(3):233-42. doi: 10.1016/s0923-2516(06)80034-8. Res Virol. 1993. PMID: 8395076

6

Blood transfusion and human immunodeficiency virus (HIV) antigen.

Courouce AM, Bouchardeau F, Jullien AM, Faucher V, Lentzy M. Courouce AM, et al. Among authors: bouchardeau f. Ann Intern Med. 1988 May;108(5):771-2. doi: 10.7326/0003-4819-108-5-771_2. Ann Intern Med. 1988. PMID: 3358585 No abstract available.

7

[Frequency of anti-HBV, CMV, and HTLV antibodies in donors at risk].

Couroucé AM, Bouchardeau F, Schaffar L. Couroucé AM, et al. Among authors: bouchardeau f. Rev Fr Transfus Immunohematol. 1984 Sep;27(4):521-4. doi: 10.1016/s0338-4535(84)80151-8. Rev Fr Transfus Immunohematol. 1984. PMID: 6095412 French.

8

The use of hepatitis B vaccine as booster for donors immune to HBV for the production of hepatitis B immunoglobulin (HBIG).

Couroucé AM, Bouchardeau F, Le Marrec N, Boulard G, Soulier JP. Couroucé AM, et al. Among authors: bouchardeau f. Dev Biol Stand. 1983;54:333-40. Dev Biol Stand. 1983. PMID: 6228472

9

Significance of NS3 and NS5 antigens in screening for HCV antibody.

Courouce AM, Bouchardeau F, Girault A, Le Marrec N. Courouce AM, et al. Among authors: bouchardeau f. Lancet. 1994 Apr 2;343(8901):853-4. Lancet. 1994. PMID: 7511195 No abstract available.

10

Efficacy of HCV core antigen detection during the preseroconversion period.

Couroucé AM, Le Marrec N, Bouchardeau F, Razer A, Maniez M, Laperche S, Simon N. Couroucé AM, et al. Among authors: bouchardeau f. Transfusion. 2000 Oct;40(10):1198-202. doi: 10.1046/j.1537-2995.2000.40101198.x. Transfusion. 2000. PMID: 11061855

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

39 results

Search Page